Vincent Perrone | executive |
Elizabeth Barrett | executive |
Mark Schoenberg | executive |
Jeffrey Bova | executive |
Dong Kim | executive |
Leland Gershell | analyst |
Raghuram Selvaraju | analyst |
Boris Peaker | analyst |
Kyuwon Choi | analyst |
Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Vincent Perrone, Head of Investor Relations.
You may begin.
Thank you, operator.